Background Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its eff ects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the effi cacy and safety of the combination of simvastatin plus ezetimibe in such patients.
Introduction
Chronic kidney disease is associated with an increased risk of cardiovascular disease, 1,2 but little is known about the prevention of cardiovascular disease in patients with chronic kidney disease. 3 Meta-analyses of randomised trials undertaken mainly in patients without chronic kidney disease have shown that statin therapy reduces the risks of major coronary events (myocardial infarction or death from coronary heart disease), ischaemic strokes, and coronary revascularisations by about one fi fth for each 1 mmol/L reduction in LDL cholesterol, while producing little eff ect on haemorrhagic strokes or vascular causes of death other than coronary heart disease. 4, 5 In people with an estimated glomerular fi ltration rate (eGFR) greater than 60 mL/min per 1·73 m², in whom the cause of cardiovascular disease is typically atherosclerotic, the proportional eff ects of statin therapy on vascular events seem to be independent of renal function. 5, 6 But, when eGFR falls below about 30 mL/min per 1·73 m², a diff erent cardiovascular pathology emerges, with vascular stiff ness and calcifi cation, structural heart disease, and sympathetic overactivity contributing to an increasing risk of cardiac arrhythmia and heart failure. 2 A key question, therefore, is whether LDL-cholesterol-lowering therapy remains eff ective as renal impairment progresses.
The SHARP (Study of Heart and Renal Protection) trial aimed to assess the safety and effi cacy of reducing LDL cholesterol in more than 9000 patients with chronic kidney disease. To achieve an average reduction in LDL cholesterol of about 1 mmol/L without the use of high statin doses (which are associated with an increased risk of myopathy, 7 especially in patients with impaired renal function 8 ), a low dose of a statin (simvastatin 20 mg daily)
was combined with a cholesterol-absorption inhibitor 9 (ezetimibe 10 mg daily). The biochemical effi cacy and tolerability of this regimen was fi rst confi rmed in the UK-HARP pilot studies.
10,11

Methods
Trial design and participants
Details of the SHARP trial objectives, design, and methods have been reported previously. 12 Patients aged 40 years and older were eligible to participate if they had chronic kidney disease with more than one previous measurement of serum or plasma creatinine of at least 150 μmol/L (1·7 mg/dL) in men or 130 μmol/L (1·5 mg/dL) in women, whether receiving dialysis or not. Potentially eligible patients attended a screening visit at which medical history and other eligibility criteria were checked, written informed consent obtained, and non-fasting blood samples taken for local laboratory assays. Single-blind study placebo tablets were provided for a 6-week run-in period to identify potential non-compliers who could be excluded before randomisation, with a consequent improvement in statistical sensitivity. 13 Ethical approval was obtained from all study sites prior to enrolment.
Randomisation and masking
At the end of the run-in period, patients who agreed to continue were allocated the study treatment by the local study laptop computer with minimised randomisation 14 (which balanced for age, sex, ethnic origin, dialysis vs non-dialysis, prior vascular disease, previous diabetes, systolic blood pressure, creatinine, and total cholesterol). Patients entering SHARP were initially randomised three ways between simvastatin 20 mg plus ezetimibe 10 mg daily, simvastatin 20 mg daily, and placebo to assess the safety of adding ezetimibe to simvastatin during the fi rst year (with no safety concerns identifi ed 12 ) and those initially allocated simvastatin alone were then rerandomised to simvastatin 20 mg plus ezetimibe 10 mg daily versus placebo after 1 year (fi gure 1). A doubledummy method ensured that patients and study staff were unaware of the treatment allocation, with all patients taking two tablets during the fi rst year (an active simvastatin plus ezetimibe tablet with a placebo simvastatin tablet; a placebo simvastatin plus ezetimibe tablet with an active simvastatin tablet; or a placebo simvastatin plus ezetimibe tablet with a placebo simvastatin tablet) and, after the fi rst year, one tablet (active or placebo simvastatin plus ezetimibe).
Procedures
After randomisation between August, 2003, and August, 2006, participants were to be seen in the study clinics for routine follow-up checks and blood safety monitoring at 2, 6, and 12 months, and then every 6 months for at least 4 years in total, until the fi nal follow-up visits between March and August, 2010. An early recall visit could also be arranged for any participant requiring additional review. At each follow-up, compliance with study treatment was estimated, any unexplained muscle pain and non-study treatment recorded, and weight and blood pressure measured. Samples of non-fasting blood were taken for local laboratory assay of creatine kinase, liver transaminase, and creatinine. Central laboratory assays of lipid profi le were conducted at randomisation in samples obtained from all participants, in about 10% of participants attending study visits at 1 and 4 years after the initial randomisation, and from all participants attending the 2·5-year visit. Diff erences between the treatment groups in average blood lipid concentrations were based on comparisons between all patients allocated simvastatin plus ezetimibe and all allocated placebo, irrespective of whether they were still compliant (with any missing data imputed from the initial randomisation values, on the basis of the assumption of non-compliance).
Information was recorded at each follow-up about any suspected myocardial infarction, stroke, vascular procedure, cancer, other reasons for hospital admissions, or other serious adverse events. If a participant became unwilling or unable to attend the follow-up visits, information about serious adverse events was obtained from them (or their relative or carer) by telephone or from their own doctors until the scheduled end of the study. Local study staff then sought extra information from hospital records and other appropriate sources about all reports of serious adverse events that might relate to study outcomes (ie, death, myocardial infarction, cardiac arrest, angina, heart failure, stroke, transient ischaemic attack, revascularisation procedures, angiography, amputation, initiation of dialysis, kidney transplant, renal failure, cancer, myopathy, rhabdomyolysis, hepatobiliary conditions). This information was sent to the international coordinating centre for central adjudication, in accordance with prespecifi ed defi nitions, by trained clinicians who were masked to study treatment allocation.
Statistical analysis
The annual incidence of major vascular events in SHARP (defi ned as non-fatal myocardial infarction or any cardiac death, any stroke, or any arterial revascularisation excluding dialysis access procedures) was projected to be about 3·7%. A study with at least 1100 such events and all patients followed up for at least 4 years was estimated to have 90% power to detect a 20% proportional reduction at p<0·01. For the reasons given in the statistical analysis plan published before unmasking, 12 the steering committee decided that the key study outcome should be changed to major atherosclerotic events (defi ned as non-fatal myocardial infarction or coronary death, non-haemorrhagic stroke, or arterial revascularisation excluding dialysis access procedures) and the key comparison should be between all patients ever allocated simvastatin plus ezetimibe versus placebo (including those initially allocated simvastatin; fi gure 1). Assessments of effi cacy and safety were to be intention-to-treat comparisons. 15, 16 Time-to-event analyses used log-rank methods 15, 16 to calculate two-sided p values, event rate ratios, and 95% CIs. Exploratory analyses that made allowance for variation in the size of the LDL cholesterol reductions achieved within subgroups of patients involved rate ratios per mmol/L reduction derived through weighting by subgroup-specifi c LDL cholesterol diff erences at the study midpoint (2·5 years). 4, 5 Analyses were done with in-house C++ programs and verifi ed with SAS version 9.1 and R version 2.2.1.
This study is registered at ClinicalTrials.gov, NCT00125593, and ISRCTN54137607. 
Role of the funding source
The main funding source (Merck/Schering-Plough Pharmaceuticals) participated in initial discussions about trial design, contributed two non-voting observers to the steering committee, and had a right to comment on (but not require changes to) study reports. It had no involvement in data collection, analysis, and interpretation, report writing, or the decision to submit for publication, and will not receive an unmasked copy of the trial database. Voting members of the steering committee, all of whom are authors, accept full responsibility for the content of this paper.
Results
Overall, 9270 patients were randomly assigned to simvastatin plus ezetimibe (4650 patients, 4193 initially plus 457 after 1 year) versus placebo (4620 patients, 4191 initially plus 429 after 1 year; fi gure 1). Among these patients, all variables were well balanced between randomised groups ( Compliance was defi ned as at least 80% of the scheduled simvastatin plus ezetimibe or placebo tablets having been taken since the previous follow-up. Among the patients allocated simvastatin plus ezetimibe, 3403 (77%) of 4435 at the end of the fi rst year of follow-up and 2397 (68%) of 3512 at the end of the fourth year remained compliant or were taking a non-study statin and, at the study midpoint (2·5 years), 2864 (71%) of 4058 were taking simvastatin plus ezetimibe or a non-study statin (table 2) . By contrast, in patients allocated placebo, 124 (3%) of 4162 patients at the end of the fi rst year and 447 (14%) of 3278 at the end of the fourth year were taking a non-study statin and, at the study midpoint, the average *In patients initially allocated to simvastatin, no 1-year sample was collected, while samples scheduled for collection at 2·5 and 4 years were collected at 1·5 and 3 years after rerandomisation. Table 2 : Average use of study simvastatin plus ezetimibe or non-study statin and average change in plasma LDL cholesterol from baseline, by period of follow-up use was 9% (341 of 3735 patients). Hence, the average diff erence in the proportion taking simvastatin plus ezetimibe or non-study statin was 61% (table 2) . As a result, the intention-to-treat comparisons assess the eff ects of around two-thirds of participants actually taking LDL-cholesterol-lowering treatment daily, which yielded an average LDL cholesterol diff erence of 0·85 mmol/L (SE 0·02; table 2). The average use of simvastatin plus ezetimibe or non-study statin did not vary much among diff erent types of patient (webappendix p 1), except that the average use was lower in patients who were on dialysis than in those who were not (54% vs 65%), which, taken together with the lower baseline LDL cholesterol concentration in patients on dialysis (2·6 vs 2·9 mmol/L), yielded a smaller average LDL cholesterol reduction (0·60 vs 0·96 mmol/L; webappendix p 1).
During the scheduled treatment period, there were 526 (11·3%) fi rst major atherosclerotic events (non-fatal myocardial infarction or coronary death, nonhaemorrhagic stroke, or arterial revascularisation) among the 4650 participants allocated simvastatin plus ezetimibe compared with 619 (13·4%) among the 4620 allocated placebo, corresponding to a signifi cant 17% proportional reduction (RR 0·83, 95% CI 0·74-0·94; log-rank p=0·0021; fi gure 2 and fi gure 3). There was also a signifi cant one-sixth reduction in major vascular events (ie, major atherosclerotic events plus non-coronary cardiac deaths and haemorrhagic strokes: 
(2·5%) 0·26
For the individual sites, multiple continuity corrected p values are reported; any value that is based on data from more than fi ve patients could have yielded a value less than 0·05 by chance. Uncorrected p values that are less than the inverse of the number of such tests were therefore corrected by multiplying by the number of such tests to correct for this multiplicity of comparisons. In all cases, this yielded p values of 1·0. *Includes two versus one cases and one versus zero deaths due to cancer in a transplanted kidney. †Excludes 18 (0·4%) versus 14 (0·3%) deaths from cancers diagnosed before randomisation. atherosclerotic events in particular clinical circumstances, so subgroup analyses were planned only as tertiary assessments. 12 There was not good evidence that the proportional eff ects on major atherosclerotic events diff ered between patients on dialysis and not (χ 1 ²=1·3, p=0·25; fi gure 4), and nor were there trends towards smaller proportional reductions in patients not on dialysis with lower eGFR (trend χ 1 ²=0·12, p=0·73) or higher urinary albumin excretion (trend χ 1 ²=0·38, p=0·54; fi gure 4). Conventionally signifi cant trends in the proportional eff ect of allocation to simvastatin plus ezetimibe were observed for subgroups defi ned by total cholesterol (trend χ 1 ²=9·01, p=0·0027) and body-mass index (trend χ 1 ²=4·04, p=0·04). After adjustment for the subgroup-specifi c LDL cholesterol reductions, the χ 1 ² statistics were reduced but remained conventionally signifi cant for total cholesterol (p=0·02; webappendix p 3).
Allocation to simvastatin plus ezetimibe was associated with non-signifi cantly fewer cardiac deaths ( 
Discussion
The SHARP results show that lowering LDL cholesterol with the combination of simvastatin plus ezetimibe safely reduces the risk of major atherosclerotic events in a wide range of patients with chronic kidney disease. As in people without kidney disease, the proportional reduction in major atherosclerotic events produced by a given absolute reduction in LDL cholesterol is broadly similar irrespective of age, sex, diabetes, history of 12 (0·3%) 27 (0·6%) 0·02
ULN=upper limit of normal. *Myopathy, defi ned as creatine kinase greater than ten times the ULN with muscle symptoms, occurred in nine (0·19%) versus fi ve (0·11%) patients, of whom eight (0·17%) versus three (0·06%) were taking allocated treatment (and not taking any non-study statin) at the time of the event (both p=NS); for rhabdomyolysis, defi ned as myopathy with creatine kinase greater than 40 times the ULN (and hence included in counts of myopathies), the corresponding numbers were four (0·09%) versus one (0·02%) and four (0·09%) versus none, again both p=NS. †Consecutive increases of alanine or aspartate transaminase greater than three times the ULN. Table 4 : Eff ects of allocation to simvastatin plus ezetimibe on muscle and hepatobiliary system vascular disease, and presenting lipid profi le. The SHARP results are relevant, therefore, to most patients with chronic kidney disease (panel). The eff ects of lowering LDL cholesterol with a statin in populations without chronic kidney disease have been described by the Cholesterol Treatment Trialists' (CTT) Collaboration, and show that statin therapy reduces the risk of myocardial infarction or coronary death, stroke, or coronary revascularisation by about a fi fth per 1 mmol/L LDL cholesterol reduction. 5 In the SHARP trial, an average reduction of 0·85 mmol/L yielded a signifi cant 17% reduction in major atherosclerotic events, which is similar to the eff ects seen in the CTT with statin regimens of equivalent LDLlowering effi cacy. The reduction in non-fatal myocardial infarction or coronary death (RR 0·92, 95% CI 0·76-1·11) in SHARP was not statistically signifi cant, but the trial lacked power for separate assessment of components of major athero sclerotic events, and the confi dence interval is consistent with the results of the CTT meta-analysis. 5 The signifi cant one-quarter reduction in coronary revascularisation pro cedures (p=0·0027) in SHARP suggests that the reduction in coronary disease refl ects a real benefi t. Similarly, the signifi cant one-quarter reduction in ischaemic strokes (p=0·0073) is consistent with the one-fi fth reduction reported in previous statin trials. 5 There was no overall reduction in the risk of vascular mortality in SHARP, but this fi nding is again what would be expected if, as seen in the CTT analyses, reduction of LDL cholesterol reduces coronary mortality but has little eff ect on other vascular causes of death. 5 Only 181 (24%) of 749 vascular deaths in SHARP were regarded as defi nitely attributable to coronary disease, so the expected eff ect of treatment on vascular mortality was very small and would have needed a much larger trial for its detection.
SHARP did not have suffi cient power to assess the eff ects on major atherosclerotic events separately in dialysis and non-dialysis patients, but there was not good statistical evidence that the proportional eff ects in dialysis patients diff ered to those seen in patients not on dialysis. Moreover, since about a third of the patients who were not on dialysis at baseline began dialysis during the trial (with about one third of those doing so within the fi rst year), the eff ects of simvastatin plus ezetimibe in the dialysis subgroup are reinforced by the favourable results in the non-dialysis subgroup. It is also important in any comparison of the eff ects on vascular outcomes in diff erent circumstances to make allowance for any diff erences in the achieved absolute LDL cholesterol reduction (which meta-analyses suggest is the chief determinant of the proportional reduction in atherosclerotic events 4, 5 ). Lower baseline LDL cholesterol concentrations and less average use of LDL-cholesterollowering therapy led to absolute reductions in LDL cholesterol that were about a third smaller in those on dialysis (0·60 mmol/L) than in those not on dialysis (0·96 mmol/L). After weighting for these LDL cholesterol reductions, the proportional reductions in major atherosclerotic events per 1 mmol/L LDL cholesterol reduction were similar: 25% (RR 0·75, 95% CI 0·56-1·00) for stage 3; 21% (RR 0·79 95% CI 0·63-0·98) for stage 4; 24% (RR 0·76, 95% CI 0·48-1·18) for stage 5; and 16% (RR 0·84, 95% CI 0·62-1·13) in patients on dialysis, respectively, with a test for trend across these four groups that was not signifi cant (χ 1 ²=0·23, p=0·63; webappendix p 3). The absence of any trend towards larger benefi t in patients with less severe renal impairment is also consistent with the fi nding that a quarter of cardiac deaths were coronary at each stage of chronic kidney disease. Taken together, the available data suggest that the most appropriate estimate of the reduction in major atherosclerotic events, both in patients on dialysis and those who are not, is the overall 19% reduction per 1 mmol/L LDL cholesterol reduction (webappendix p 3).
Before completion of the SHARP trial, two trials of statin regimens in patients on haemodialysis (4D 19 and AURORA 20 ), and one trial in patients who had undergone renal transplantation (ALERT 21 ), had not detected signifi cant benefi ts in their primary outcomes. At fi rst sight, these fi ndings might appear to be discrepant with our results, but the LDL-cholesterol-weighted proportional eff ects on particular vascular outcomes in these three trials and SHARP were statistically compatible for
Panel: Research in context
Systematic review
The Cholesterol Treatment Trialists' collaborative meta-analysis of individual participant data from 26 randomised trials 5 has shown that lowering LDL cholesterol with a statin regimen reduces the risk of myocardial infarction, coronary death, ischaemic stroke, and coronary revascularisation procedures by about a fi fth per 1 mmol/L LDL cholesterol reduction in a wide range of people. However, none of the three trials [19] [20] [21] in patients with chronic kidney disease included in that meta-analysis reported a signifi cant reduction in its primary vascular disease outcome, leading to uncertainty about whether lowering of LDL cholesterol is eff ective in renal patients.
Interpretation
The SHARP randomised trial has now shown that lowering of LDL cholesterol with simvastatin plus ezetimibe safely reduces the risk of major atherosclerotic events in a wide range of patients with chronic kidney disease. When the SHARP results are compared with those of the previous statin trials in renal patients, it appears that the absence of signifi cant reductions in earlier trials could have been due both to the much smaller number and the much smaller proportion of vascular events in their primary outcomes that were related to atherosclerosis and, hence, preventable by lowering of LDL cholesterol.
non-fatal myocardial infarction, non-fatal haemorrhagic stroke, non-fatal non-haemorrhagic stroke, coronary revascular isation (which was not part of the primary outcomes of the 4D and AURORA trials), and any vascular death (p values non-signifi cant for all heterogeneity tests; fi gure 6). Moreover, the eff ects on particular vascular outcomes in these four renal trials were compatible with those recorded in the trials of statin therapy in non-renal populations that were included in the CTT meta-analysis. 5 Consequently, the failure to achieve statistical signifi cance in the previous renal trials might derive from both the much smaller number and the much smaller proportion of modifi able vascular events in their primary outcomes: whereas more than 
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Events (% per annum)
Risk ratio per mmol/L LDL-C reduction
Control better 99% or 95% CI Figure 6 : Eff ects of LDL-lowering therapy on particular vascular outcomes in four trials in patients with chronic kidney disease and 23 trials in other patients Data from the Cholesterol Treatment Trialists' Collaboration. 5 χ² tests are shown for heterogeneity between rate ratios for each outcome in the four trials (4D, 19 ALERT, 21 AURORA, 20 and SHARP) in patients with chronic kidney disease. MI=myocardial infarction. LDL-C=LDL-cholesterol.
half the primary outcomes in 4D and AURORA were vascular deaths (for which there were small, and nonsignifi cant, benefi ts), about three-quarters in SHARP were non-fatal atherosclerotic events (for which there were clear benefi ts). The previous trials of statin therapy have shown that the proportional reduction in risk is chiefl y determined by the absolute reduction in LDL cholesterol, and that more intensive LDL reduction yields further reductions in risk. 4, 5 Addition of ezetimibe to a statin reduces LDL cholesterol by the equivalent of around three doublings of the statin dose. 22 It therefore off ers a potentially useful method of increasing benefi ts in high-risk populations in which raising the statin dose is not desirable, either because the dose is already high or, as in chronic kidney disease, because of concerns about drug toxicity. The design of SHARP incorporated a three-way randomised comparison with a simvastatin-alone group for the fi rst year so that adverse eff ects of the addition of ezetimibe to simvastatin could be assessed; as reported previously, no serious safety concerns emerged during this period. 12 A more reliable assessment of the safety of the simvastatin plus ezetimibe combination is now provided by comparison with placebo among all 9270 patients in SHARP during 4·9 years of follow-up. There was no evidence of any excess risk of persistent increase of hepatic transaminases, of hepatitis, of gallstones, or of pancreatitis. Patients with chronic kidney disease are at increased risk of statin-induced myopathy, 8 but in the SHARP trial the excess incidence of myopathy was only about two per 10 000 patients per year of treatment with simvastatin plus ezetimibe.
While the SHARP trial was in progress some investigators had postulated, on the basis of post-hoc analyses of the SEAS trial 23 of simvastatin plus ezetimibe versus placebo in patients with aortic stenosis, that ezetimibe might increase the risk of cancer. This hypothesis-generating observation was not supported at the time by a hypothesis-testing meta-analysis 24 of interim data for unadjudicated cancers that had occurred by July, 2008, in SHARP and the IMPROVE-IT trial of simvastatin plus ezetimibe versus simvastatin among patients with acute coronary syndromes. 25 The current results from SHARP involve substantially larger numbers of cancers than were available for that previous meta-analysis and, again, provide no credible evidence of any excess risk of cancer or of death from cancer, either overall or at any particular site, and no evidence of any trend towards an increased risk with longer exposure to study treatment (webappendix p 4). Nor was there any evidence of any excess risk of death from particular non-vascular causes. Overall, therefore, the combination of simvastatin plus ezetimibe allowed LDL cholesterol to be lowered substantially, but safely, in a group of patients at high risk of vascular disease.
During SHARP, allocation to simvastatin plus ezetimibe reduced LDL cholesterol by an average of 0·85 mmol/L over about 5 years, yielding a reduction of 17% in major atherosclerotic events, which is equivalent to a one-fi fth risk reduction per mmol/L reduction in LDL cholesterol. On average, however, only two-thirds of the patients allocated simvastatin plus ezetimibe were taking an LDL-cholesterol-lowering regimen and so, with full compliance, the LDL cholesterol reduction would typically have been about 1·3 (ie, 0·85×3/2) mmol/L. This calculation implies that patients with chronic kidney disease who take simvastatin plus ezetimibe as prescribed would typically reduce their risk of major atherosclerotic events by about a quarter (ie, 17%×3/2). In SHARP, the annual risk of a major atherosclerotic event in both patients on dialysis and those who were not exceeded the 2% threshold that is widely recommended for LDLcholesterol-lowering therapy 26 and a reduction of one quarter in risk in patients similar to those studied would correspond to the prevention of 30-40 major atherosclerotic events per 1000 patients treated for 5 years. Moreover, the absolute benefi t would be even larger in renal patients with a previous history of coronary heart disease, who were excluded from SHARP, but whose absolute risk is two-or-three times higher. These benefi ts are substantial and suggest that widespread use of LDL-cholesterol-lowering therapy in patients with chronic kidney disease would result in a worthwhile reduction in cardiovascular disease complications in this high-risk population.
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